HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"). The Group adopted “one horizontal, one vertical” as its core business strategy: horizontally, it extended a lean management system to advance multi-mode collaboration among medical institution alliances; vertically, it focused on specialty-specific innovation in medical diagnostics to fast-track the translation and implementation of new technologies and products. Meanwhile, the Group leveraged AI to enhance the comprehensive solutions for medical institution alliances, promoted the practical application of AI in healthcare scenarios, and continuously strengthened the value of empowering clinical practices, demonstrating strong operational resilience.In the first half of 2025, due to multiple factors, including the centralized drug-procurement program, cost controls of medical insurance, and fierce market competition, the Group’s short-term results did not meet expectations. However, the Group remained committed to product and business model innovation, and further refined the mechanisms and processes of its operational management. By adhering to lean operations, the overall performance has achieved significant improvements. During the Reporting Period, the Group’s gross profit margin reached approximately 34.0%, representing an improvement of approximately 4.4% over the overall gross profit margin for 2024. The net loss amounted to RMB55.4 million, a significant decrease of 56.1% compared to the same period last year. The joint construction business remained the Group’s largest business segment, which recorded the revenue of RMB180.3 million, accounting for 57.6% of the total revenue, increased by approximately 9.6% as compared with the same period last year, achieving significant outcomes in empowering medical alliance clients through in-depth services, paving the way for the Group’s long-term high-quality growth. During the Reporting Period, the Group’s diagnostic testing services recorded revenue of RMB313.2 millionSteadily implementing “one horizontal, one vertical” strategy, with notable achievements in hospital-enterprise partnerships“One horizontal” ——Extending lean management system to deepen diverse forms of collaboration within medical institution alliancesYunkang has been committed to developing an innovative service mode for the joint construction of medical institution alliances featuring “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. During the Reporting Period, the Group provided nearly 450 alliance clients with multi-scenario solutions tailored to different clinical needs, including AI+ digital intelligence solutions for medical institution alliances, comprehensive collaborations with medical laboratories, solutions for regional/pathology centers and precision medicine center, and specialty-based solutions for alliance development, among other multi-model collaboration services. By leveraging Yunkang’s strengths, the Group assisted healthcare institutions at all levels in enhancing service capabilities and expanding service coverage, established a hierarchical and coordinated healthcare service system, and promoted the development of regional hierarchical diagnosis and treatment services.During the Reporting Period, despite increasingly fierce market competition, the Group maintained solid growth in the joint construction business through continuous deep collaboration with leading hospitals and municipal and county-level hospitals, further consolidating its competitive advantage.“One vertical” ——Joint innovation platform for diagnostic testing serves as strong driver for R&DThe Group has always focused on “clinical needs”, continuously strengthening hospital-enterprise collaboration and pioneering the establishment of a joint innovation platform for diagnostic testing, driving business expansion and product competitiveness. During the Reporting Period, the Group forged joint diagnostic innovation partnerships with dozens of top-tier medical institutions nationwide, delivering a portfolio of testing products addressing multiple infectious syndromes, including respiratory tract infections, central nervous system infections, urinary tract infections, gynecological infections, and tuberculosis, as well as genetic testing products for personalized medication. Collectively, these innovative products have served nearly 300 clients across the country, and achieved sustained growth in testing revenue.During the Reporting Period, Yunkang and Guangdong Provincial People’s Hospital successively launched a series of new panel products covering respiratory tract infections, central nervous system infections, and invasive fungal infections, successfully creating a standardized incubation model for domestic hospital-enterprise research innovation and translation, as well as a “1+N” medical inspection collaboration network. Moreover, throughout the process of scientific and technological innovation, both parties have gained rich clinical experience. With the active involvement and sustained efforts of dozens of domestic diagnostic experts and scholars, they formulated the Expert Consensus on the Application of tNGS for Clinical Standardization, which was published during the Reporting Period in Chinese Journal of Laboratory Medicine, a leading journal in China’s diagnostic field. During the Reporting Period, Yunkang also maintained close collaboration with the First Affiliated Hospital of Guangzhou Medical University, one of China’s top-tier hospitals, and successfully developed a urinary tNGS product, advancing the clinical practice of precision diagnosis and treatment for urinary tract infections. Simultaneously, Yunkang partnered with the First Affiliated Hospital of Jinan University to establish a “university-hospital-enterprise joint innovation platform” and incubated and operated the “innovation project of psychiatric drug genetic testing”, which has successfully yielded genetic testing products for antidepressants, anti-anxiety drugs, and sedative-hypnotics.AI empowers multi-modal solutions for medical institution alliances, improving quality and efficiency to deepen client services  During the Reporting Period, Yunkang fully employed DeepSeek and achieved digital deployment across its platforms. Centered on the core concepts of “AI+” and “precision diagnostics”, Yunkang extensively applied artificial intelligence technology across the multi-technology platforms of its medical laboratories. Taking the in-depth integration of AI technology with Yunkang pathology diagnosis platform as an example, the per-slide efficiency of AI-empowered diagnostic was continuously optimized, achieving simultaneous improvements in intelligence, efficiency, and quality. Moreover, through the deployment of intelligent applications, Yunkang realized smart online customer services and the efficient review of results and reports, which fully streamlined diagnostic service processes and improved experience and satisfaction of its client services. In the process of jointly developing new technologies and products through hospital-enterprise R&D, Yunkang’s AI technology empowered product innovation and R&D across multiple aspects, including bioinformatics analysis, report interpretation, disease risk assessment, and development and translation of novel products, by leveraging the powerful data analysis, modeling, and predictive capabilities of large-scale AI models. This has accelerated the clinical implementation.Notably, Yunkang unveiled its medical AI model “ZhiYun” developed in collaboration with Runda Medical and Huawei, spanning the entire clinical workflow from pre-diagnosis to diagnosis and post-diagnosis. It will provide more efficient and convenient support and experience across all stages of clinical medical services. Meanwhile, Yunkang signed a strategic cooperation agreement with Runda Medical to strengthen in-depth collaboration across the industrial ecosystems in “AI + IVD + healthcare services”, jointly promoting the development and application of large-scale AI models in the medical field, and providing clients with digital-intelligence healthcare solutions. In the future, “ZhiYun”, the medical AI model, will be piloted in Yunkang’s healthcare partners and gradually rolled out nationwide, to improve quality and efficiency of medical institution alliance operations.Future prospects2025 marks the final lap for implementing the 14th Five-Year Plan. China has accelerated the capacity expansion of premium healthcare resources and their extension to lower-tier markets, resulting in a more balanced regional distribution. The country has also expedited the development of medical institution alliances and driven their upgrade from “framework building” to “high-quality operation”. Clinical treatment is also shifting from “broad-spectrum therapies” to “precision medicine”, with the growth potential of the industry continuing to be realized. At the same time, AI technology has continued to empower hierarchical diagnosis and treatment services, and the industry is embracing new growth opportunities.  Looking ahead, Yunkang will continue to keep pace with industry development trends and align with national policies, further strengthening the value of empowering clinical practices, and persistently exploring the “product innovation + business innovation” dual-pronged model to accelerate business development, deeply empower medical testing services, and benefit more residents.Yunkang Group Limited (Stock Code: 2325)Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to nearly 450 on-site diagnostic centers. As of June 30, 2025, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

Toronto, ON, August 28, 2025 - (ACN Newswire via SeaPRwire.com) - Digital Shovel, a leading innovator in crypto mining infrastructure solutions, is thrilled to announce the successful completion of its partnership with IREN (formerly Iris Energy Limited), marked by the delivery of the final batch totaling 493 MW of busway sets, including active units and spares. This milestone, achieved well ahead of schedule, underscores Digital Shovel’s commitment to excellence and reliability in supporting next-generation data center operations.The partnership, formalized in February 2024, saw Digital Shovel supply IREN with almost 500 MW of busways, critical to powering IREN’s expanding data centers, which are optimized for Bitcoin mining and AI cloud services using 100% renewable energy. The project was completed without delays, with deliveries consistently surpassing expectations, enabling IREN to advance its operational timeline.“We are incredibly proud of the seamless execution of this partnership with IREN,” said Scot Johnson, CEO of Digital Shovel. “Delivering all 493 MW of busway sets ahead of schedule is a testament to our team’s dedication and the strength of our innovative solutions. IREN’s vision for sustainable, high-performance data centers aligns perfectly with our mission, and we’re excited about the impact this project will have on their growth.”The early completion of this contract also positions both companies for future collaboration. “This project has been a fantastic opportunity to showcase what we can achieve together,” Johnson added. “We’re eager to explore new ventures with IREN as they continue to lead in renewable energy-powered data centers for Bitcoin mining and AI applications.”The success of this deployment lays the foundation for expanded collaboration as demand for infrastructure solutions continues to surge. With proven capacity to deliver at scale and speed, Digital Shovel is positioned to help power the next generation of energy-efficient data centers across North America.For more information about Digital Shovel and its solutions, please visit www.digitalshovel.com.About Digital ShovelDigital Shovel is a leading vertically integrated HPC, AI and Bitcoin Mining systems manufacturer, building critical elements for datacenter construction. This includes turnkey modular datacenters, as well as infrastructure including switchgear, Smart PDUs, busway systems and more. For more info, visit www.DigitalShovel.com About IRENIREN (NASDAQ: IREN), formerly Iris Energy Limited, is an Australia-based company operating next-generation data centers powered by 100% renewable energy. With facilities optimized for Bitcoin mining, AI cloud services, and other power-dense computing applications, IREN is a global leader in sustainable, high-performance data center solutions. For more information, visit www.iren.com.Media Contact:Press@DigitalShovel.comhttps://www.digitalshovel.com  Copyright 2025 ACN Newswire via SeaPRwire.com.

SAN DIEGO, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - The YFQ-42A Collaborative Combat Aircraft, designed and developed by General Atomics Aeronautical Systems, Inc. (GA-ASI), is now conducting flight testing in coordination with the U.S. Air Force. This historic achievement continues the company's rapid creation of new, jet-powered uncrewed platforms chartered by the U.S. Air Force (USAF) to achieve air dominance while being designed for rapid production, in large quantities, at an affordable price."What a great moment for the U.S. Air Force and for GA-ASI," said GA-ASI President David R. Alexander. "It's been our collaboration that enabled us to build and fly the YFQ-42A in just over a year. It's an incredible achievement and I salute the Air Force for its vision and I salute our development team for delivering yet another historic first for our company."The YFQ-42A is GA-ASI's newest uncrewed jet, focused on air-to-air semi-autonomous operation and based on the genus-species concept pioneered on the XQ-67A Off-Board Sensing Station (OBSS). Using state-of-the-art, model-based digital engineering, GA-ASI was able to accelerate its schedule while optimizing air dominance capabilities. YFQ-42's autonomy core has been trained across more than five years of flight testing using GA-ASI's jet-powered MQ-20 Avenger®, an aircraft no other company has. The integrated capabilities of a stealthy, air-to-air-focused uncrewed jet, combined with a learned AI autonomy core, provide warfighters with a definitive advantage in the future fight.The GA-ASI program has focused on creating a high-rate production environment that enables USAF to reach its goal of producing more than 1,000 CCAs on an accelerated timeline. Ground testing for YFQ-42A began in May.USAF selected GA-ASI in April 2024 to build and fly a fully production-representative Collaborative Combat Aircraft (CCA). In March, USAF designated the aircraft the YFQ-42A, with the "Y" indicating a production-representative aircraft ("Y" will be dropped upon entering production), "F" signifying a fighter aircraft, and "Q" denoting an uncrewed aircraft.GA-ASI has developed more than two dozen different types of uncrewed aircraft and delivered more than 1,200 units to customers, building more than 100 aircraft per year at its 5 million-square-foot manufacturing facility in Poway, Calif. GA-ASI aircraft have amassed nearly 9 million total flight hours; more than 50 GA-ASI aircraft are aloft around the world every minute of every day.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging nearly 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc. registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 27, 2025 - (ACN Newswire via SeaPRwire.com) - TechInnovation® 2025, Singapore’s preeminent platform for innovation and business transformation, returns for its 13th edition from 29–31 October 2025 at Sands Expo & Convention Centre, Level 3 Heliconia and Hibiscus Ballroom, Singapore. Organised by IPI Singapore, the three-day event will bring together over 40 expert speakers, more than 100 breakthrough technologies and curated programmes designed to accelerate real-world innovation and cross-border collaboration.Building on last year’s momentum, which brought together more than 100 exhibitors from 8 countries, attracted attendees from 42 markets, and resulted in over 30 projects supported by IPI Singapore after the event, TechInnovation 2025 will once again convene innovators, startups, corporates, and government agencies across Asia to showcase emerging technology solutions and forge strategic partnerships. In 2024, notably, 46 percent of visitors were senior management decision-makers, underscoring the event’s position as a high-value marketplace for business and technology leaders.The event focuses on sectors including smart buildings, urban solutions, engineering, digital health, sustainability, advanced manufacturing and AI, ensuring businesses can find solutions tailored to their growth ambitions while engaging directly with innovation leaders, potential collaborators and funding partners. Anchored on the theme Discover, Connect and Collaborate, TechInnovation 2025 offers exhibitors and visitors a platform to showcase ready-to-market technologies, connect with potential partners across borders, and co-create solutions to address real-world challenges faced by businesses.Innovation in Action: Interactive BoothsDebuting this year, TechInnovation 2025 will feature experiential technology showcases, giving select exhibitors the chance to showcase their ready-to-market technologies in a hands-on, interactive format. These interactive spaces are designed to spark conversations, encourage engagements and foster meaningful connections across the show floor. For SMEs, the booths offer a unique opportunity to showcase innovations, build credibility and connect directly with potential partners and customers. The launch responds to strong demand for immersive, real-world demonstrations that make technology tangible and memorable.Call for ExhibitorsTechInnovation 2025 invites technology providers, research institutions, startups and solution developers to participate as exhibitors. Exhibitors will benefit from exposure to thousands of decision-makers and industry leaders, targeted business matching opportunities and media visibility through IPI Singapore’s pre-event publicity and digital campaigns.“TechInnovation brings together enterprises and partners to explore new ideas,” said Michael Goh, Chief Operating Officer of IPI Singapore. “We look forward to welcoming exhibitors whose innovations can support practical business applications and contribute to a more sustainable and competitive future.”About TechInnovation 2025Returning for its 13th edition, TechInnovation 2025 is the flagship event of IPI Singapore, connecting technology seekers and providers across Asia. The event serves as a dynamic marketplace for co-innovation and tech adoption, drawing participation from startups, SMEs, corporates, universities and government agencies.This year’s theme, “Discover, Connect, Collaborate” underscores TechInnovation’s mission to drive growth through discovery, global connection and collaboration. The event will feature over 40 speakers, more than 100 technologies and 3 days of programming designed to scale real-world business innovation. TechInnovation is organised by IPI Singapore, a subsidiary of Enterprise Singapore and catalyst of Singapore’s open innovation ecosystem.TechInnovation® is a registered trademark of IPI Singapore.Learn more at www.techinnovation.com.sg.About IPI SingaporeIPI Singapore is an innovation catalyst that creates opportunities for enterprises to grow beyond boundaries. As a subsidiary of Enterprise Singapore, IPI Singapore accelerates the innovation process of enterprises through access to its global innovation ecosystem and advisory services.With a strong belief that innovation is key to enterprise growth, IPI Singapore provides enterprises with access to innovative ideas and technologies. IPI Singapore also facilitates and supports enterprises' innovation processes, including commercialisation and go-to-market strategies.Learn more at https://www.ipi-singapore.org/Media Contact:Sheree TanManager, Marketing & Communications, PartnershipsIPI Singapore ipi_comms@ipi-singapore.orgTheodore WoonDirectorPINPOINT PR Pte. Ltd.theodore@pinpointpr.global Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - On August 27, CALB Group Co., Ltd. ("CALB" or "the Company," stock code: 3931.HK) announced its unaudited condensed consolidated interim results for the six months ended 30 June 2025 (the "Reporting Period"). During the Reporting Period, the Company delivered outstanding operational performance with revenue of RMB16,418.88 million, representing an increase of 31.7% compared to the same period last year, and realized a profit of RMB752.99 million, representing a year-on-year increase of 80.4%. In the first half of 2025, the Company showed strong profitability and resilience during the accelerated trend of transformation of global renewable energy development.According to SNE Research, the Company’s installed capacity of globally EV batteries in the first half of 2025 increased 22.7%, ranking third domestically and fourth globally, with the monthly installed capacity reaching 4.7GWh. The Company was particularly outstanding in the domestic passenger vehicle market with the market share hitting new highs in June and July, reaching 7.4% and 8.25%, respectively. In the energy storage sector, the Company's growth was even more rapid. According to InfoLink, the Company’s shipment in the first half of the year ranked fourth globally, achieving milestone development in the energy storage sector.Centered on continuous technological breakthroughs and with the launch of multiple major products, in the first half of 2025, the Company maintained its leadership in cutting-edge battery technology with the “UP” battery. At the same time, the Company’s 400Wh/kg solid-liquid hybrid battery is poised for mass production and commercial deployment, while significant progress has been made in the all-solid-state battery—including breakthroughs in R&D and the commissioning of a dedicated production line. CALB’s high-power lithium iron phosphate R46 large cylindrical battery is the first in the industry to achieve mass production and has successfully achieved mass production for the latest PHEV models from Geely and Dongfeng. At the same time, the Company’s next-generation lithium manganese LFP battery product achieves an energy density exceeding 210Wh/kg and will also go into mass production. With improved performance, the product can attain 10%- 80% charging within 15 minutes.In the passenger vehicle market, leveraging exceptional product capabilities, the Company achieved full entry into the world’s top three automakers, namely Volkswagen, Hyundai and Toyota. In the first half of 2025, its 800V 5C batteries achieved a monthly sales volume of over 20,000 packs, which will support models for XPeng, Ledao, Leapmotor, Audi, BAIC, and others, and the 800V 5C high-voltage NCM battery exclusively supports popular models such as XPeng’s new P7 with ultra-long range, helping XPeng’s new P7 create a new world record of driving 3,971km in 24 hours.In the commercial vehicle market, CALB has established a comprehensive product matrix architecture for “ZHIYUAN” batteries, covering all scenarios, all applications, and all capabilities. In the first half of year, the Company’s domestic commercial vehicle installed capacity has increased by 310% year-on-year. CALB is the first in the industry to launch a million-kilometer customized products for light trucks, significantly improving the quality assurance of battery systems and effectively enhancing product competitiveness in the market. Leveraging the outstanding recognition from the light truck field, the Company has established in-depth collaborations with customers such as Chery, Geely, Ruichi, Foton, Dongfeng, Changan, and King Long. In the heavy truck field, the Company has deeply cultivated the market through the scenario-based power consumption design and has achieved full-spectrum collaboration by partnering with customers such as Sinotruk, XCMG, SANY, Shaanxi Automobile, Jiefang, Dongfeng, Lingong, and Liugong.The Company has made significant breakthroughs in the international market, and its energy storage business achieved rapid growth in the first half of year. The 314Ah second-generation long-cycle energy storage cell can achieve an ultra-long service life of 15,000 cycles and high energy efficiency of over 96%, while achieving zero degradation in the first 1,000 cycles, earning high recognition from customers for both the product and delivery capabilities. In terms of the overseas market, the Company has successfully partnered with the largest power plant projects in Latin America and South Africa, entering the supplier lists of several leading developers and power grid companies. Meanwhile, the Company’s next-generation “ZHIJIU” of 588Ah and 600Ah+ large energy storage cells will scheduled for mass production within the year.In addition, the Company is the first in the industry to pass the eVTOL power battery manufacturing compliance review and supports the development of China’s low-altitude economy market by actively exploring emerging markets. At present, the R46 cylindrical battery cell with an energy density of 310Wh/kg is now in mass production for leading eVTOL customers in the industry. At the same time, CALB signed a deepened strategic cooperation agreement with GOVY, under which the two parties will carry out in-depth collaboration in the eVTOL sector and jointly promote the development of standardized eVTOL energy products.Overall, in the first half of the year, CALB focused on the strategy of consolidating its leadership in products and technologies, while accelerating the globalization of its production capacity layout. At present, its battery Pack plant in Thailand has been put into operation, while construction of the Portugal base officially commenced in the first quarter of 2025. Looking ahead, with the further improvement of industrial chain system, the Company is expected to leverage its cross-domain, cross-scenario dynamic storage product matrix to achieve deep synergy in its dynamic storage business, creating cutting-edge product capabilities across all scenarios. At the same time, the Company will continuously explore emerging markets such as rail transit, mining, low-altitude flight, and humanoid robots by offering high-safety, high-reliability, and high-performance product solutions. Furthermore, CALB will continue to advance the implementation of its “energy+” strategy, further consolidating its leading position in the global new energy industry.About CALBCALB is a new energy enterprise specializing in the research, production, sales, and market application development of lithium batteries, battery management systems, and related integrated products and lithium battery materials. As Battery Expert, we aim to build a comprehensive energy operation system, to provide complete product solutions and full life-cycle management for the new energy application market, represented by power and energy storage.Currently, CALB has completed an all-round layout in domestic by setting up industrial bases in Changzhou, Xiamen, Wuhan, Chengdu, Hefei, Jiangmen and Meishan. Meanwhile, CALB has set up bases in Europe and ASEAN, vigorously expanding the layout all over the world to become a global leading enterprise with large-scale intelligent manufacturing capabilities. Copyright 2025 ACN Newswire via SeaPRwire.com.